RKLB vs. AZN
RKLB (Rocket Lab USA, Inc.) and AZN (AstraZeneca PLC) are both stocks. RKLB operates in Aerospace & Defense (Industrials), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 3 years, RKLB returned 179.23%/yr vs 9.54%/yr for AZN. At a 0.10 correlation, their price movements are largely independent.
Performance
RKLB vs. AZN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RKLB achieves a 62.92% return, which is significantly higher than AZN's 0.81% return.
RKLB
- 1D
- 3.24%
- 1M
- 7.76%
- YTD
- 62.92%
- 6M
- 120.42%
- 1Y
- 292.98%
- 3Y*
- 179.23%
- 5Y*
- —
- 10Y*
- —
AZN
- 1D
- -2.37%
- 1M
- -0.71%
- YTD
- 0.81%
- 6M
- 1.53%
- 1Y
- 28.04%
- 3Y*
- 9.54%
- 5Y*
- 12.08%
- 10Y*
- 15.85%
RKLB vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RKLB Rocket Lab USA, Inc. | 62.92% | 173.89% | 360.58% | 46.68% | -69.30% | 6.14% |
AZN AstraZeneca PLC | 0.81% | 43.30% | -0.62% | 1.44% | 19.14% | -0.46% |
Correlation
The correlation between RKLB and AZN is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Aug 25, 2021 | 0.10 |
Fundamentals
RKLB:
$68.81B
AZN:
$283.40B
RKLB:
-$0.33
AZN:
$6.66
RKLB:
92.89
AZN:
4.69
RKLB:
30.39
AZN:
5.99
RKLB:
$679.58M
AZN:
$60.44B
RKLB:
$248.43M
AZN:
$49.37B
RKLB:
-$177.36M
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RKLB vs. AZN — Risk / Return Rank
RKLB
AZN
RKLB vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rocket Lab USA, Inc. (RKLB) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RKLB | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.09 | ||
| Sortino ratioReturn per unit of downside risk | +1.34 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.21 | +0.17 |
| Calmar ratioReturn relative to maximum drawdown | 6.86 | 1.83 | +5.03 |
| Martin ratioReturn relative to average drawdown | 15.94 | 4.90 | +11.04 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RKLB | AZN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.20 | 1.11 | +2.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.51 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.64 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.76 | 0.49 | +0.26 |
Drawdowns
RKLB vs. AZN - Drawdown Comparison
The maximum RKLB drawdown since its inception was -82.96%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for RKLB and AZN.
Loading charts...
Drawdown Indicators
| RKLB | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.96% | -48.94% | -34.02% |
Max Drawdown (1Y)Largest decline over 1 year | -43.01% | -15.43% | -27.58% |
Max Drawdown (3Y)Largest decline over 3 years | -55.49% | -27.87% | -27.62% |
Max Drawdown (5Y)Largest decline over 5 years | — | -27.87% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -27.87% | — |
Current DrawdownCurrent decline from peak | -24.35% | -12.90% | -11.45% |
Average DrawdownAverage peak-to-trough decline | -51.40% | -11.37% | -40.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.48% | 5.75% | +12.73% |
Volatility
RKLB vs. AZN - Volatility Comparison
Rocket Lab USA, Inc. (RKLB) has a higher volatility of 41.86% compared to AstraZeneca PLC (AZN) at 7.42%. This indicates that RKLB's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RKLB | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 41.86% | 7.42% | +34.44% |
Volatility (6M)Calculated over the trailing 6-month period | 72.23% | 17.47% | +54.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 92.32% | 25.55% | +66.77% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.48% | 24.02% | +57.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 81.48% | 24.94% | +56.54% |
Dividends
RKLB vs. AZN - Dividend Comparison
RKLB has not paid dividends to shareholders, while AZN's dividend yield for the trailing twelve months is around 2.93%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.93% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
RKLB Rocket Lab USA, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
RKLB vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Rocket Lab USA, Inc. and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RKLB vs. AZN - Profitability Comparison
RKLB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported a gross profit of 76.49M and revenue of 200.35M. Therefore, the gross margin over that period was 38.2%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
RKLB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported an operating income of -55.97M and revenue of 200.35M, resulting in an operating margin of -27.9%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
RKLB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported a net income of -45.02M and revenue of 200.35M, resulting in a net margin of -22.5%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
Frequently Asked Questions
RKLB and AZN have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RKLB has higher volatility (41.86%) compared to AZN (7.42%). In terms of maximum drawdown, RKLB dropped -82.96% vs AZN's -48.94%.
RKLB currently has the higher Sharpe Ratio (3.20 vs 1.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RKLB and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer